Who are the top shareholders of the Dr Lalchand. Lab?

The top shareholder of Dr Lalchand Lab is Arjan Lal Chandani, with a 42.53% stake, followed by public shareholder Amit Charan at 5.08%. Individual investors own 45.68% of the company, with no institutional or pledged promoter holdings.

The top shareholders of Dr Lalchand Lab include Arjan Lal Chandani, who holds the largest stake at 42.53%. Following him, the highest public shareholder is Amit Charan, with a holding of 5.08%. Additionally, individual investors collectively own 45.68% of the company. Notably, there are no institutional holdings from mutual funds or foreign institutional investors, and there are no pledged promoter holdings.

how big is Dr Lalchand. Lab?

As of Jun 06, Dr Lalchandani Labs Ltd has a market capitalization of 6.00 Cr, classifying it as a Micro Cap company, with shareholder's funds of 9.54 Cr and total assets of 14.99 Cr; however, no recent financial data is available for the latest four quarters.

Market Cap: As of Jun 06, Dr Lalchandani Labs Ltd has a market capitalization of 6.00 Cr, which classifies it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: There is no valid Consolidated or Standalone financial data available for the latest four quarters, including Net Sales and Net Profit.<BR><BR>Balance Sheet Snapshot: This is Standalone data for the reporting period of Mar'24. The Shareholder's Funds are valued at 9.54 Cr, and the Total Assets amount to 14.99 Cr.

Who are in the management team of Dr Lalchand. Lab?

As of March 2022, the management team of Dr Lalchand Lab includes Arjan Lalchandani (Chairman & Managing Director), Mohit Lalchandani (Whole Time Director & CEO), Anchal Gupta (Executive Director & CFO), and independent directors Rajiv Handa and Prakash Jhuraney, along with director Swati Chandra.

As of March 2022, the management team of Dr Lalchand. Lab includes the following individuals:<BR><BR>1. Arjan Lalchandani - Chairman & Managing Director<BR>2. Mohit Lalchandani - Whole Time Director & CEO<BR>3. Anchal Gupta - Executive Director & CFO<BR>4. Rajiv Handa - Independent Director<BR>5. Prakash Jhuraney - Independent Director<BR>6. Swati Chandra - Director<BR><BR>These members play key roles in the governance and operational management of the company.

What does Dr Lalchand. Lab do?

Dr Lalchandani Labs Ltd provides pathology laboratory services and operates as a micro-cap company with a market cap of Rs 6 Cr. It was established in 2011 and transitioned to a limited company in 2017.

Overview: <BR>Dr Lalchandani Labs Ltd operates in the healthcare services industry, specifically providing pathology laboratory services, and is classified as a micro-cap company.<BR><BR>History: <BR>Dr Lalchandani Labs Ltd was originally incorporated as a partnership firm in New Delhi on 15 September 2011 under the name Dr. A Lalchandani Pathology Laboratories. The partnership was taken over by Dr Lalchandani Labs Ltd on 2nd August 2017, as per the agreement dated 31st August 2017. Revenue and profit data are not available for the latest quarter.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: N/A <BR>Most recent Net Profit: N/A <BR>Market-cap value: Rs 6 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 6.00 <BR>Industry P/E: 54 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.11 <BR>Return on Equity: 4.40% <BR>Price to Book: 0.64<BR><BR>Contact Details: <BR>Address: M-20 Basement, Greater Kailash-1, New Delhi, 110048 <BR>Tel: 91-11-49057058 <BR>Email: info@lalchandanipathlab.com <BR>Website: http://www.lalchandanipathlab.com

Has Dr Lalchand. Lab declared dividend?

No Dividend History Available

Who are the peers of the Dr Lalchand. Lab?

Dr. Lalchand Lab's peers include Syngene Intl., Dr. Lal Pathlabs, and Metropolis Health, among others. It has average management risk and below-average growth, with a 1-year return of -42.86%, significantly lower than its peers.

Peers: The peers of Dr Lalchand. Lab are Syngene Intl., Dr Lal Pathlabs, Poly Medicure, Indegene, Vijaya Diagnost., Metropolis Healt, Thyrocare Tech., Suven Life Scie., Vimta Labs.<BR><BR>Quality Snapshot: Excellent management risk is observed at Dr Lal Pathlabs, while Good management risk is found at Syngene Intl., Poly Medicure, Indegene, Vijaya Diagnost., Metropolis Healt, Thyrocare Tech., and Vimta Labs, and the rest. Average management risk is noted for Vimta Labs and Dr Lalchand. Lab, while Below Average management risk is seen at Suven Life Scie. In terms of Growth, Excellent growth is found at Vimta Labs, while Average growth is observed at Poly Medicure, Indegene, and the rest. Below Average growth is noted for Syngene Intl., Dr Lal Pathlabs, Vijaya Diagnost., Metropolis Healt, Thyrocare Tech., Dr Lalchand. Lab, and Suven Life Scie.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Suven Life Scie. at 161.15%, while Dr Lalchand. Lab has the lowest at -42.86%. This indicates that Dr Lalchand. Lab's performance is significantly lower than its peers. Additionally, the six-month return is negative for Syngene Intl., Poly Medicure, Metropolis Healt, and Dr Lalchand. Lab.

What is the technical trend for Dr Lalchand. Lab?

As of June 2, 2025, Dr. Lalchand Lab's trend is mildly bearish, influenced by daily moving averages and mixed signals from MACD and Bollinger Bands, with weekly indicators showing mild bullishness and monthly indicators remaining bearish.

As of 2 June 2025, the technical trend for Dr Lalchand. Lab has changed from bearish to mildly bearish. The weekly MACD is mildly bullish, but the monthly MACD remains bearish, indicating mixed signals. The daily moving averages are mildly bearish, while the weekly Bollinger Bands are bullish, contrasting with the monthly Bollinger Bands that are mildly bearish. The KST shows a mildly bullish stance on the weekly chart but is bearish on the monthly. Dow Theory indicates no trend on the weekly and mildly bullish on the monthly. Overall, the current stance is mildly bearish, driven primarily by the daily moving averages and the mixed signals from MACD and Bollinger Bands.

When is the next results date for Dr Lalchand. Lab?

Dr Lalchand. Lab will announce its results on 14 November 2025.

Dr Lalchand. Lab is scheduled to declare its results on 14 November 2025.

How has been the historical performance of Dr Lalchand. Lab?

Dr Lalchand. Lab has experienced a decline in net sales and profitability, with total operating income dropping from 11.28 Cr in Mar'22 to 4.45 Cr in Mar'25, and profit before tax decreasing from 1.25 Cr to 0.40 Cr in the same period. Total assets and liabilities also decreased, while cash flow from operating activities remained stagnant, though a net cash inflow of 1.00 Cr was recorded in Mar'25.

Answer:<BR>The historical performance of Dr Lalchand. Lab shows a declining trend in net sales and profitability over the past few years, with a significant drop in total operating income from 11.28 Cr in Mar'22 to 4.45 Cr in Mar'25. The operating profit margin has fluctuated, peaking at 28.9% in Mar'24 before falling to 23.37% in Mar'25. Profit before tax also saw a decline, moving from 1.25 Cr in Mar'22 to 0.40 Cr in Mar'25, while profit after tax decreased from 0.93 Cr in Mar'22 to 0.42 Cr in Mar'25. The company’s total assets decreased from 18.12 Cr in Mar'22 to 15.75 Cr in Mar'25, and total liabilities also saw a reduction from 18.12 Cr to 15.75 Cr in the same period. Cash flow from operating activities has been stagnant, with no inflow reported in the last two years, although there was a net cash inflow of 1.00 Cr in Mar'25.<BR><BR>Breakdown:<BR>Dr Lalchand. Lab's financial performance has shown a notable decline in net sales, which decreased from 11.28 Cr in Mar'22 to 4.45 Cr in Mar'25. This decline is reflected in the total operating income, which also fell significantly over the years. The operating profit margin peaked at 28.9% in Mar'24 but dropped to 23.37% in Mar'25, indicating challenges in maintaining profitability. Profit before tax decreased from 1.25 Cr in Mar'22 to 0.40 Cr in Mar'25, while profit after tax followed a similar trend, moving from 0.93 Cr to 0.42 Cr. The company's total assets decreased from 18.12 Cr in Mar'22 to 15.75 Cr in Mar'25, with total liabilities also reducing in the same timeframe. Cash flow from operating activities has remained stagnant, with no inflow in recent years, although a net cash inflow of 1.00 Cr was recorded in Mar'25, suggesting some improvement in liquidity.

Which are the latest news on Dr Lalchand. Lab?

Why is Dr Lalchand. Lab falling/rising?

As of 04-Dec, Dr Lalchandani Labs Ltd's stock price is Rs 19.22, down 4.99%, and has significantly underperformed the Sensex over the past month. Despite increased investor participation, the stock shows short-term weakness and is facing downward pressure.

As of 04-Dec, Dr Lalchandani Labs Ltd's stock price is falling, currently at Rs 19.22, reflecting a decrease of Rs 1.01 or 4.99%. This decline is evident in the stock's performance over the past week, where it has underperformed the benchmark Sensex, which only fell by 0.53%. Additionally, the stock has experienced a significant drop of 14.23% over the past month, contrasting sharply with the Sensex's gain of 2.16% during the same period.<BR><BR>Today's trading session has shown erratic behavior, with the stock opening down by 4.99% and reaching an intraday low of Rs 19.22. The stock has not traded on five days out of the last twenty, indicating a lack of consistent trading activity. Although the stock is trading higher than its 100-day and 200-day moving averages, it is lower than its 5-day, 20-day, and 50-day moving averages, suggesting a short-term weakness.<BR><BR>Despite a rise in investor participation, with delivery volume increasing by 130.77% compared to the 5-day average, the overall market sentiment appears negative, contributing to the stock's decline. The combination of these factors indicates that Dr Lalchandani Labs Ltd is currently facing downward pressure on its stock price.

Is Dr Lalchand. Lab overvalued or undervalued?

As of December 4, 2025, Dr Lalchand Lab's valuation has improved to attractive, indicating it is undervalued with a PE ratio of 19.83, an EV to EBITDA of 8.75, and a Price to Book Value of 0.84, making it more affordable compared to peers like Max Healthcare and Apollo Hospitals, while also outperforming the Sensex with a year-to-date return of 13.73%.

As of 4 December 2025, the valuation grade for Dr Lalchand. Lab has moved from risky to attractive, indicating a significant improvement in its investment appeal. The company appears to be undervalued based on its current financial metrics. Notable ratios include a PE ratio of 19.83, an EV to EBITDA of 8.75, and a Price to Book Value of 0.84, which suggest that the stock is trading at a discount relative to its earnings and assets.<BR><BR>When compared to peers, Dr Lalchand. Lab's valuation stands out positively. For instance, Max Healthcare is classified as very expensive with a PE ratio of 74.46, while Apollo Hospitals, also attractive, has a PE of 61.81. This comparison highlights Dr Lalchand. Lab's relative affordability in the healthcare services sector. Additionally, the company's recent stock performance shows a year-to-date return of 13.73%, outperforming the Sensex's 9.12%, reinforcing the notion that it may be undervalued in the current market.